Sandoz Talks US Biosimilars And Misinformation
Q&A With Hillel Cohen, Sandoz' Executive Director, Scientific Affairs
Increasing access and use of lower cost biosimilars by combatting disparagement and misinformation is more important now than ever, as the COVID-19 pandemic cripples economies across the globe, argues Sandoz’ executive director for scientific affairs, Hillel Cohen.
